| Basics |
ABBVIE INC.
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
|
| IPO Date: |
December 14, 2012 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$408.76B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.00 | 1.01%
|
| Avg Daily Range (30 D): |
$1.88 | 0.82%
|
| Avg Daily Range (90 D): |
$1.86 | 0.91%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
6.25M |
| Avg Daily Volume (30 D): |
4.3M |
| Avg Daily Volume (90 D): |
3.92M |
| Trade Size |
| Avg Trade Size (Sh.): |
106 |
| Avg Trade Size (Sh.) (30 D): |
49 |
| Avg Trade Size (Sh.) (90 D): |
50 |
| Institutional Trades |
| Total Inst.Trades: |
62,190 |
| Avg Inst. Trade: |
$10.02M |
| Avg Inst. Trade (30 D): |
$30.37M |
| Avg Inst. Trade (90 D): |
$30.53M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
19 |
| Market Closing Trades |
| Avg Closing Trade: |
$85.55M |
| Avg Closing Trade (30 D): |
$256.43M |
| Avg Closing Trade (90 D): |
$231.61M |
| Avg Closing Volume: |
768.88K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$.52
|
$.72
|
|
Diluted EPS
|
|
$.52
|
$.72
|
|
Revenue
|
$
|
$ 15.42B
|
$ 13.34B
|
|
Gross Profit
|
$
|
$ 11.08B
|
$ 9.34B
|
|
Net Income / Loss
|
$
|
$ 941M
|
$ 1.29B
|
|
Operating Income / Loss
|
$
|
$ 4.89B
|
$ 3.73B
|
|
Cost of Revenue
|
$
|
$ 4.35B
|
$ 4B
|
|
Net Cash Flow
|
$
|
$ 1.29B
|
$ -349M
|
|
PE Ratio
|
|
|
|
|
|
|
